ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

Obesity Clinical Trial

Official title:

ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04890873
• Other study ID #: ERX1000-C-002
• Status: Completed
• Phase: Phase 1
• Start date: October 17, 2019
• Est. completion date: July 3, 2023

Study information

• Verified date: October 2023
• Source: ERX Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: July 3, 2023
• Est. primary completion date: July 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.

• Adult females and males, of any race, between 18 and 55 years of age, inclusive, at Screening.

• Females of non-childbearing potential, which is defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or with bilateral tubal ligation or Essure® (hysteroscopic bilateral tubal occlusion) with confirmation of occlusion of the fallopian tubes performed at least 3 months prior to Screening, or postmenopausal (defined as at least 12 months post cessation of menses without an alternative medical cause and follicle-stimulating hormone [FSH] level

= 40 mIU/mL). Males will agree to use contraception and refrain from sperm donation.

• Body mass index between 30.0 and 39.9 kg/m^2, inclusive, at Screening.

• Glycosylated hemoglobin (HbA1c) level of < 6.5% at Screening (test may be repeated once for confirmation of out-of-range values).

• Vital signs at Screening and Check-in as per the following ranges and stable (measured in a supine position after a minimum of 5 minutes of rest):

1. Systolic blood pressure = 90 and = 140 mmHg

2. Diastolic blood pressure = 50 and = 90 mmHg

3. Pulse rate = 50 and = 100 bpm.

• In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by the Investigator (or designee).

Exclusion Criteria:

• Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dose administration on Day 1.

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).

• Obesity induced by known endocrine or genetic disorders (eg, Cushing syndrome, hypothyroidism, Prader Willi syndrome).

• Any previous surgical treatment or procedures with medical devices (such as insertion of lap band or gastric balloons) for obesity (excluding liposuction if performed > 1 year prior to Check-in).

• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, which would increase the subject's risk of participation.

• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair > 6 months prior to Screening will be allowed).

• History or evidence of underlying liver disease, including viral (hepatitis B and C) or alcoholic hepatitis, or confirmed diagnosis of nonalcoholic steatohepatitis (NASH); nonalcoholic fatty liver disease with qualifying liver function tests (LFTs) will be allowed.

• Gilbert's Syndrome (congenital non-hemolytic hyperbilirubinemia) or suspicion of Gilbert's Syndrome based on total and direct bilirubin.

• Laboratory results that exceed the following thresholds at Screening AND Check-in (laboratory tests may be repeated once for confirmation of out-of-range values) as specified:

1. alanine aminotransferase (ALT) > 1.5 × upper limit of normal (ULN)

2. aspartate aminotransferase (AST) > 1.5 × ULN

3. gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin, or International Normalized Ratio (INR) > ULN

4. Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration < 13.0 g/dL [130 g/L] for males, < 11.0 g/dL [110 g/L] for females) at Screening or any other condition known to interfere with interpretation of HbA1c measurement

5. Neutrophils < 1.5 × 109/L deemed clinically significant by Investigator upon a confirmatory repeat

6. Thyroid-stimulating hormone (TSH) level above the normal range, confirmed on repeat.

• History or presence of cardiac arrhythmia (at the discretion of the Investigator) or congenital long QT syndrome.

• A QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec for males or > 470 msec for females on Screening ECG. At the discretion of the Investigator, ECG may be repeated twice and an average taken of the 3 readings.

• The subject has creatinine clearance = 80 mL/minute as calculated using the Cockroft-Gault equation. At the discretion of the Investigator, evaluation may be repeated once to confirm.

• History of alcoholism or drug/chemical abuse within 2 years prior to Check in.

• Alcohol consumption of > 14 units per week. One unit of alcohol equals 12 oz (360 mL) of beer, 1½ oz (45 mL) of liquor, or 5 oz (150 mL) of wine.

• Positive urine drug screen at Screening; or positive alcohol breath test result or positive urine drug screen at Check-in.

• Positive hepatitis B surface antigen and/or hepatitis C antibody and/or positive human immunodeficiency virus 1/2 (Appendix 2).

• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.

• Subjects who are actively dieting, have gained or lost > 5 pounds, or using or intend to use any prescription or nonprescription drugs for weight loss including herbal or other dietary supplements within 3 months prior to Check-in.

• Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in and throughout the outpatient Follow-up period.

• Use or intend to use any prescription medications/products within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).

• Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).

• Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to Check-in and throughout the outpatient Follow-up period, unless deemed acceptable by the Investigator (or designee).

• Consumption of alcohol from 72 hours prior to Check-in.

• Use of tobacco- or nicotine-containing products (including nicotine and non-nicotine e-cigarettes, vaping, etc.) within 3 months prior to Check-in, or positive cotinine at Screening or Check-in.

• Receipt of blood products within 2 months prior to Check-in.

• Donation of blood from 8 weeks prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.

• Poor peripheral venous access.

• Have previously completed or withdrawn from this study or any other study investigating ERX1000, and have previously received the investigational product.

• Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.

Related Conditions & MeSH terms

• Obesity

Intervention

Drug:
• ERX1000
ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
• Placebo
A suspension containing magnesium hydroxide carbonate in polysorbate

Locations

Country	Name	City	State
United States	Labcorp Clinical Research Unit Inc.	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
ERX Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs)		Day 1 up to end of study (Day 10)
Primary	Part A (Single Dose Group A9): Incidence of clinical laboratory abnormalities		Screening (Day -28) up to end of study (Day 10)
Primary	Part A (Single Dose Group A9): Incidence of 12-lead electrocardiogram (ECG) abnormalities		Screening (Day -28 to Day -2), Days 1, 3 and 10
Primary	Part A (Single Dose Group A9): Incidence of vital sign abnormalities		Screening (Day -28 to Day -2), Check-in (Day -1), Days 1, 3, 4, 5, 6 and 10
Primary	Part A (Single Dose Group A9): Incidence of physical examination abnormalities		Check-in (Day -1), Days 6 and 10
Primary	Part B (Multiple Dose Group B5): Incidence of 12-lead electrocardiogram (ECG) abnormalities		Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 28, 30 and 37
Primary	Part B (Multiple Dose Group B5): Incidence of vital sign abnormalities		Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 30 and 37
Primary	Part B (Multiple Dose Group B5): Incidence of physical examination abnormalities		Check-in (Day -2), Days 30, 33 and 37
Primary	Part B (Multiple Dose Group B6): Incidence of 12-lead electrocardiogram (ECG) abnormalities		Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 8, 10, 15, 17, 22, 25, 29, 34 and End of Study (Day 41)
Primary	Part B (Multiple Dose Group B6): Incidence of vital sign abnormalities		Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 25, 27, 29, 34, 38 and End of Study (Day 41)
Primary	Part B (Multiple Dose Group B6): Incidence of physical examination abnormalities		Check-in (Day -2), Days 34, 38 and End of Study (Day 41)
Primary	Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence and severity of adverse events (AEs)		Day 1 up to end of study (For Group B5, Day 37 and for Group B6, Day 41)
Primary	Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence of clinical laboratory abnormalities		Screening (Day -28), Check-in (Day-2), Days 7, 14, 21, 28, 34 and End of Study (Day 41)
Secondary	Part A (Single Dose Group A9): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-8		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-t		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Cmax		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Ctrough		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Tmax		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, t1/2		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).		Day 1, 8 and 10
Secondary	Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)		Day 1
Secondary	Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)		Day 1
Secondary	Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)		Day 1
Secondary	Part B (Multiple Dose Group B5): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-8		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-t		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Cmax		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Ctrough		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Tmax		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, t1/2		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)		Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37
Secondary	Part B (Multiple Dose Group B6): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-8		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-t		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Cmax		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Ctrough		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Tmax		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, t1/2		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).		Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)		Day 1 and Day 29
Secondary	Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)		Day 1 and Day 29
Secondary	Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)		Day 1 and Day 29
Secondary	Part B (Multiple Dose Group B5): Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight		Screening (Day -28 to Day -3), Days -1, 8, 15, 22, 28, 30, 33 and 37
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum leptin		Days -1, 7, 14, 21, 27 and 30
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL)		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL)		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Triglyceride		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum insulin		Days 7 and 21
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index		Days -1, 14 and 27
Secondary	Part B (Multiple Dose Group B6):Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight		Screening (Day -28 to -3), Days -1, 1, 8, 15, 22, 29, 34, 36, 38 and End of Study (Day 41)
Secondary	Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum leptin		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL)		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL)		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Triglyceride		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum insulin		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance		Day -1 and Day 31
Secondary	Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index		Day -1 and Day 31